GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Trinity Biotech PLC (FRA:TRB) » Definitions » Cyclically Adjusted PS Ratio

Trinity Biotech (FRA:TRB) Cyclically Adjusted PS Ratio : 0.08 (As of Jun. 08, 2024)


View and export this data going back to . Start your Free Trial

What is Trinity Biotech Cyclically Adjusted PS Ratio?

As of today (2024-06-08), Trinity Biotech's current share price is €2.12. Trinity Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €27.41. Trinity Biotech's Cyclically Adjusted PS Ratio for today is 0.08.

The historical rank and industry rank for Trinity Biotech's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:TRB' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.06   Med: 0.99   Max: 3.44
Current: 0.08

During the past years, Trinity Biotech's highest Cyclically Adjusted PS Ratio was 3.44. The lowest was 0.06. And the median was 0.99.

FRA:TRB's Cyclically Adjusted PS Ratio is ranked better than
96.65% of 477 companies
in the Medical Devices & Instruments industry
Industry Median: 2.17 vs FRA:TRB: 0.08

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Trinity Biotech's adjusted revenue per share data for the three months ended in Mar. 2024 was €30.468. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €27.41 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Trinity Biotech Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Trinity Biotech's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Cyclically Adjusted PS Ratio Chart

Trinity Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 1.00 0.36 0.24 0.09

Trinity Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.20 0.15 0.09 0.08

Competitive Comparison of Trinity Biotech's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Trinity Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trinity Biotech's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's Cyclically Adjusted PS Ratio falls into.



Trinity Biotech Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Trinity Biotech's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=2.12/27.41
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trinity Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Trinity Biotech's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=30.468/120.9901*120.9901
=30.468

Current CPI (Mar. 2024) = 120.9901.

Trinity Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 4.041 100.773 4.852
201409 4.451 100.474 5.360
201412 4.563 99.576 5.544
201503 4.940 99.975 5.978
201506 3.751 100.573 4.512
201509 3.990 100.274 4.814
201512 3.990 99.676 4.843
201603 3.685 99.676 4.473
201606 4.118 101.072 4.930
201609 4.101 100.274 4.948
201612 4.005 99.676 4.861
201703 4.022 100.374 4.848
201706 4.178 100.673 5.021
201709 4.033 100.474 4.857
201712 3.927 100.075 4.748
201803 3.688 100.573 4.437
201806 4.091 101.072 4.897
201809 3.884 101.371 4.636
201812 4.305 100.773 5.169
201903 3.827 101.670 4.554
201906 3.909 102.168 4.629
201909 4.384 102.268 5.187
201912 3.766 102.068 4.464
202003 3.762 102.367 4.446
202006 2.744 101.769 3.262
202009 5.163 101.072 6.180
202012 6.443 101.072 7.713
202103 4.745 102.367 5.608
202106 5.132 103.364 6.007
202109 4.284 104.859 4.943
202112 0.859 106.653 0.974
202203 2.896 109.245 3.207
202206 2.148 112.779 2.304
202209 2.081 113.504 2.218
202212 1.945 115.436 2.039
202303 36.257 117.609 37.299
202306 1.675 119.662 1.694
202309 1.794 120.749 1.798
202312 0.973 120.749 0.975
202403 30.468 120.990 30.468

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Trinity Biotech  (FRA:TRB) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Trinity Biotech Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Trinity Biotech (FRA:TRB) Business Description

Traded in Other Exchanges
Address
IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.

Trinity Biotech (FRA:TRB) Headlines

No Headlines